slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
221,491-221,520 of 319,975
14
The slide uses a biological structural comparison to highlight the unique binding domain of the NXC-201 product.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
15
Includes comparative data charts for transduction efficiency and signaling, and flow cytometry data for anti-exhaustion.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
16
The slide uses a longitudinal timeline comparison to highlight the superior safety and efficacy profile of NXC-201.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
17
The chart illustrates the correlation between the peak of HBI0101 cells and the subsequent drop in dFLC, a marker for AL Amyloidosis.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
18
The slide uses a causal chain to link cellular pathology to systemic organ damage.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
19
The slide uses a grouped bar chart format to highlight clinical superiority. Includes a disclaimer about cross-trial comparisons.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · ActionLoop · David Goliath1 hit
20
The slide uses a table structure to contrast patient segments and includes a bar chart visualization for patient growth.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · ActionLoop · David Goliath1 hit
21
The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · ActionLoop · David Goliath1 hit
22
Includes a footnote citing FDA approval precedents for similar single-arm studies.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · ActionLoop · David Goliath1 hit
23
Uses a visual icon-grid to represent market expansion.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · ActionLoop · Cost Of Inaction1 hit
24
Includes detailed source citations in the footer; uses color-coded bars to represent different drug therapies.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · ActionLoop · Cost Of Inaction1 hit
25
The slide uses a two-column layout to separate milestones by drug candidate.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · ActionLoop · Cost Of Inaction1 hit
26
The slide uses a standard pharmaceutical pipeline table format with clinical and preclinical segments.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
27
Includes a comparison table of clinical outcomes (ORR/CR) between NXC-201 and competitors.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
28
The slide uses a wave-like visual to represent market segments and their associated financial opportunities.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
29
Immix Biopharma | Investor Presentation Deck | 61 slidesImmix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
30
The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
31
The chart uses a grouped bar structure to compare NXC-201 (green) against competitors (blue/red) across three categories: No BCMA, Yes BCMA, and Overall.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
32
The slide uses a structured comparison table to highlight clinical advantages. It includes a disclaimer about cross-trial comparisons.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
33
The slide uses a comparative structure to present data for two distinct indications side-by-side.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
34
The chart demonstrates deepening clinical responses over time for NXC-201 therapy.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
35
The table displays clinical safety data for NXC-201, specifically focusing on Cytokine Release Syndrome and Immune cell associated Neurotoxicity.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
36
The slide highlights specific safety metrics for a competitor's product, likely to contrast with the presenter's own product profile.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
37
The diagram illustrates a dose-escalation process leading to the RP2D.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
38
The slide features a scientific illustration of cellular structures, likely representing the drug delivery mechanism.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
39
Includes scientific diagrams of molecular pathways and bar/line charts showing efficacy data.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
40
Slide presents three distinct preclinical data sets: survival in STS, tumor response in STS, and survival in KPC pancreatic cancer models.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
41
Includes a process flow diagram illustrating the mechanism of action of iMX-110 in tumor microenvironments.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
42
Includes both internal unpublished data and external reference data from Winograd et al. (2015).Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
43
Immix Biopharma | Investor Presentation Deck | 61 slidesImmix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit